 |
Charles
W. Bishop, PhD
CEO and President, Cytochroma Inc.
|
Dr. Bishop has served
as President and CEO of Cytochroma since June 2006, bringing
a wealth of management experience in the pharmaceutical industry
across multiple disciplines including Research & Development,
Regulatory Affairs, Operations, and Business Development.
Dr. Bishop co-founded Proventiv Therapeutics, LLC in September
2005 where he served as President. Proventiv Therapeutics,
LLC was acquired by Cytochroma Holdings ULC in June 2006.
During the period of September 1987 to June 2005, Dr. Bishop
held various senior management positions at Bone Care International,
Inc., a public specialty pharmaceutical company focused on
developing and commercializing vitamin D hormone therapies.
Dr. Bishop’s positions with Bone Care included President,
CEO, Director, Executive Vice President of Research and Development,
and Chief Scientific Officer. Under Dr. Bishop's direction,
Bone Care advanced a portfolio of proprietary vitamin D hormones
and analogs to varying stages of development for SHPT, metabolic
bone disease, psoriasis and cancers of the prostate, breast
and colon. Dr. Bishop was responsible for the successful
preparation and prosecution of three NDAs that ultimately
led to FDA approval of a novel vitamin D drug, named doxercalciferol,
for SHPT in dialysis patients (Hectorol® 2.5 mcg Capsules
and Hectorol® Injection) and pre-dialysis patients (Hectorol® 0.5
mcg Capsules). Prior to joining Bone Care, Dr. Bishop held
various management positions in the Health Care Division
of the Procter & Gamble Company. Dr. Bishop completed
a four-year National Institutes of Health Postdoctoral Fellowship
in vitamin D Biochemistry at the University of Wisconsin-Madison
and received his Ph.D. degree in Nutritional Biochemistry
from Virginia Polytechnic Institute and State University,
after earning an undergraduate degree in Chemistry from the
University of Virginia.
Back To Top
|
about
us